BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, Zengin N, Altiparmak E. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005; 11(4): 580-583 [PMID: 15641150 DOI: 10.3748/wjg.v11.i4.580]
URL: https://www.wjgnet.com/1007-9327/full/v11/i4/580.htm
Number Citing Articles
1
P. LANGLET, F. D’HEYGERE, J. HENRION, M. ADLER, J. DELWAIDE, H. VAN VLIERBERGHE, J. P. MULKAY, L. LASSER, R. BRENARD, Y. HORSMANS, P. MICHIELSEN, A. LAUREYS, F. NEVENS. Clinical trial: a randomized trial of pegylated‐interferon‐α‐2a plus ribavirin with or without amantadine in treatment‐naïve or relapsing chronic hepatitis C patientsAlimentary Pharmacology & Therapeutics 2009; 30(4): 352 doi: 10.1111/j.1365-2036.2009.04052.x
2
Stanislas Pol, Marc Bourlière. Optimizing Treatment Outcomes in Chronic Hepatitis C: Management of Non-ResponseAntiviral Therapy 2006; 11(8): 955 doi: 10.1177/135965350601100815
3
Silvia Fargion, Mauro Borzio, Alessandra Maraschi, Antonietta Cargnel, the participants of the Gruppo Epatologico Lombardo. Triple antiviral therapy in HCV positive patients who failed prior combination therapyWorld Journal of Gastroenterology 2006; 12(33): 5293-5300 doi: 10.3748/wjg.v12.i33.5293